Viridian Q4 2022 net loss $45.8M, cash $424.6M; THRIVE Ph3 enrolled

Viridian Therapeutics, Inc.\DE

Net loss $45.8M in Q4 2022 vs $28.9M in Q4 2021; R&D expense $39.3M vs $22.4M.
Cash, equivalents & short-term investments $424.6M as of Dec 31, 2022; runway into H2 2025.
First patient enrolled in THRIVE Phase 3 trial of VRDN-001 for active TED; topline mid-2024.
Initial proof-of-concept data for VRDN-001 in chronic TED expected Q2 2023.
Appointed Scott Myers as President and CEO in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Viridian Therapeutics, Inc.\DE reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 8, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-063737

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.